Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member
Lantheus Holdings (NASDAQ: LNTH) has appointed Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025. Dr. Morrow, currently Head of the Oncology Therapeutic Area Unit at Takeda, brings extensive expertise in clinical development and oncology therapeutics. She will serve as a member of the Board's Science and Technology Committee.
This appointment marks the second new board addition in five months, bringing the total number of directors to eleven, with nine being independent. Dr. Morrow's previous roles include Chief Medical Officer at CRISPR Therapeutics and Vice President at Amgen, where she led global therapeutic areas in oncology and related fields. She holds an M.D. from the University of Texas Medical School at Houston and completed specialized training at prestigious institutions.
Lantheus Holdings (NASDAQ: LNTH) ha nominato la Dott.ssa Phuong Khanh (P.K.) Morrow nel suo Consiglio di Amministrazione, a partire dal 1° febbraio 2025. La Dott.ssa Morrow, attualmente responsabile dell'Unità di Area Terapeutica per l'Oncologia presso Takeda, porta con sé una vasta esperienza nello sviluppo clinico e nelle terapie oncologiche. Sarà membro del Comitato per la Scienza e la Tecnologia del Consiglio.
Questa nomina segna il secondo nuovo ingresso nel consiglio in cinque mesi, portando il numero totale di direttori a undici, di cui nove indipendenti. Le precedenti esperienze della Dott.ssa Morrow includono il ruolo di Chief Medical Officer presso CRISPR Therapeutics e di Vice Presidente in Amgen, dove ha guidato le aree terapeutiche globali in oncologia e campi correlati. Ha conseguito un Dottore in Medicina presso la Scuola di Medicina dell'Università del Texas a Houston e ha completato una formazione specialistica presso prestigiose istituzioni.
Lantheus Holdings (NASDAQ: LNTH) ha nombrado a la Dra. Phuong Khanh (P.K.) Morrow en su Junta Directiva, con efecto el 1 de febrero de 2025. La Dra. Morrow, actualmente jefa de la Unidad de Área Terapéutica de Oncología en Takeda, aporta una amplia experiencia en desarrollo clínico y terapias oncológicas. Servirá como miembro del Comité de Ciencia y Tecnología de la Junta.
Este nombramiento marca la segunda incorporación al consejo en cinco meses, aumentando el número total de directores a once, de los cuales nueve son independientes. Los roles anteriores de la Dra. Morrow incluyen Directora Médica en CRISPR Therapeutics y Vicepresidenta en Amgen, donde lideró las áreas terapéuticas globales en oncología y campos relacionados. Tiene un M.D. de la Escuela de Medicina de la Universidad de Texas en Houston y completó una formación especializada en instituciones prestigiosas.
란테우스 홀딩스 (NASDAQ: LNTH)는 2025년 2월 1일부로 박사 푸옹 칸 (P.K.) 모로를 이사회에 임명했습니다. 현재 타케다에서 종양학 치료 분야의 책임자로 있는 모로 박사는 임상 개발 및 종양학 치료에 대한 광범위한 전문 지식을 보유하고 있습니다. 그녀는 이사회의 과학 및 기술 위원회의 일원으로 활동할 것입니다.
이번 임명은 5개월 간의 두 번째 신규 이사 추가로, 이사 총수는 11명으로 증가하였으며, 이 중 9명은 독립 이사입니다. 모로 박사의 이전 경력에는 CRISPR 제약에서 최고 의학 책임자(CMO)가 되었고, 암젠에서의 부사장으로 재직하며 종양학 및 관련 분야의 글로벌 치료 영역을 이끌었습니다. 그녀는 휴스턴의 텍사스대학교 의과대학에서 의학 박사(M.D.)를 취득했으며, 유명 기관에서 전문 교육을 이수했습니다.
Lantheus Holdings (NASDAQ: LNTH) a nommé le Dr Phuong Khanh (P.K.) Morrow au sein de son Conseil d'Administration, à compter du 1er février 2025. Le Dr Morrow, actuellement responsable de l'Unité des domaines thérapeutiques en oncologie chez Takeda, apporte une vaste expertise en développement clinique et en thérapies oncologiques. Elle sera membre du Comité scientifique et technologique du Conseil.
Cette nomination marque le deuxième ajout au conseil en cinq mois, portant le nombre total de directeurs à onze, dont neuf sont indépendants. Les précédents postes du Dr Morrow comprennent celui de Directeur Médical chez CRISPR Therapeutics et Vice-présidente chez Amgen, où elle a dirigé des domaines thérapeutiques globaux en oncologie et dans des domaines connexes. Elle détient un M.D. de la Faculté de Médecine de l'Université du Texas à Houston et a complété une formation spécialisée dans des institutions prestigieuses.
Lantheus Holdings (NASDAQ: LNTH) hat Dr. Phuong Khanh (P.K.) Morrow mit Wirkung zum 1. Februar 2025 in den Aufsichtsrat berufen. Dr. Morrow, die derzeit die Einheit für Onkologie-Therapie bei Takeda leitet, bringt umfassende Fachkenntnisse in der klinischen Entwicklung und in der Onkologie-Therapie mit. Sie wird Mitglied des Wissenschafts- und Technologieraums des Aufsichtsrats sein.
Diese Ernennung markiert die zweite Neuzugänge im Aufsichtsrat innerhalb von fünf Monaten, wodurch die Gesamtzahl der Direktoren auf elf steigt, von denen neun unabhängig sind. Dr. Morrows vorherige Positionen umfassen die des Chief Medical Officer bei CRISPR Therapeutics und Vizepräsidentin bei Amgen, wo sie globale Therapiegebiete in der Onkologie und verwandten Bereichen leitete. Sie hat einen M.D. von der Universität von Texas Medical School in Houston und hat eine spezialisierte Ausbildung an namhaften Institutionen abgeschlossen.
- Addition of experienced pharmaceutical executive with deep oncology expertise
- Strengthening of board independence with 9 out of 11 directors being independent
- Strategic alignment with company's focus on radiopharmaceutical development
- None.
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus’ Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board’s Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus’ strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent.
“Lantheus is excited to welcome P.K. Morrow to our Board of Directors – the second new board appointment in the past five months – during this pivotal period of growth and innovation in radiopharmaceuticals,” said Mary Anne Heino, Chairperson of the Board. “Dr. Morrow’s extensive expertise in drug development and her significant experience in oncology align well with our vision for the future of Lantheus and will be essential in our Purpose to Find, Fight and Follow disease to deliver better patient outcomes."
“I look forward to joining the Lantheus Board and partnering with a dedicated team of patient-centric leaders who are focused on advancing the Company’s research and development capabilities to support its innovative pipeline,” said Dr. Morrow. “With a strong legacy in precision diagnostics and radiopharmaceuticals and the recent announcement of two strategic deals, I am confident that Lantheus is well-positioned to continue its growth as a fully integrated radiopharmaceutical company, while making an impact on the lives of patients with difficult-to-treat disease.”
Dr. Morrow is currently the Head of the Oncology Therapeutic Area Unit (OTAU) at Takeda, where she is responsible for the company’s oncology R&D strategy and development portfolio. Prior to joining Takeda, Dr. Morrow served as Chief Medical Officer at CRISPR Therapeutics, where she led a cross-functional team of physicians, scientists and development team members, overseeing end-to-end development of clinical programs spanning hematology, oncology, diabetes and cardiovascular diseases states. Dr. Morrow previously spent over a decade at Amgen, where she served as Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone Diseases. Before joining the industry, she held the role of Assistant Professor, Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Morrow received an M.D. from the University of Texas Medical School at Houston. She completed her internal medicine residency at Baylor College of Medicine and a Hematology/Oncology Fellowship at the University of Texas MD Anderson Cancer Center, where she received the Clifton D. Howe (Fellow of the Year) Award, the American Society of Clinical Oncology Young Investigator Award, and served as the Lyndon Baines Johnson Chief Fellow.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “continue,” “execute,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
FAQ
When will Dr. P.K. Morrow join Lantheus (LNTH) Board of Directors?
How many independent directors does LNTH have after Dr. Morrow's appointment?
What is Dr. Morrow's current role before joining LNTH's board?
Which committee will Dr. Morrow serve on Lantheus' board?
How many new board members has LNTH appointed in the past five months?
